恩度联合紫杉醇、卡培他滨治疗晚期胃癌合并腹膜转移的疗效分析

Analysis on the clinical efficacy of Endostar combined with paclitaxel and capecitabine in the treatment of advanced gastric cancer with peritoneal metastasis

目的探讨恩度联合紫杉醇、卡培他滨治疗晚期胃癌合并腹膜转移的疗效。方法对60例晚期胃癌合并腹膜转移患者的临床资料进行回顾性分析,根据治疗方案的不同将其分为试验组(n=32)和对照组(n=28)。对照组患者采用紫杉醇联合卡培他滨方案,试验组患者采用恩度联合紫杉醇、卡培他滨方案,比较两组患者的近期临床疗效和不良反应发生情况。结果治疗后,试验组患者的有效率(RR)为62.5%,高于对照组患者的17.9%,差异有统计学意义(χ~2=5.323,P<0.05);试验组患者的疾病控制率(DCR)为81.3%,高于对照组患者的28.6%,差异有统计学意义(χ~2=5.715,P<0.05)。试验组和对照组患者的不良反应总发生率分别为56.3%(18/32)和71.4%(20/28),两组比较,差异无统计学意义(χ~2=0.287,P>0.05)。治疗后,试验组患者肿瘤标志物癌胚抗原(CEA)、糖类抗原72-4(CA72-4)的含量下降程度均较对照组明显(P<0.05);两组患者血清肿瘤标志物CEA、CA72-4的含量比较,差异均有统计学意义(P<0.05)。结论恩度联合紫杉醇、卡培他滨治疗晚期胃癌合并腹膜转移患者的近期临床疗效好,DCR高,不良反应少,安全性高,值得临床推广。

Objective To explore the efficacy of Endostar in combination with paclitaxel and capecitabine in the treatment of patients with advanced gastric cancer and peritoneal metastasis. Method The clinical data of 60 patients with advanced gastric cancer and peritoneal metastases were retrospectively analyzed, and were stratified as study group（n=32）and control group（n=28）. The regimen of paclitaxel ＋ capecitabine was administered for control group, while the study group was treated with Endostar combined with paclitaxel and capecitabine, the short-term clinical efficacy and incidence of adverse reactions were compared between the two groups. Result After treatment, the response rate（RR） in study group was 62.5%, which was higher than that in control group at 17.9%, the difference was statistically significant（χ-2=5.323, P〈0.05）; the disease control rate（DCR） was 81.3% in study group, and was higher than 28.6% in control group,showing statistically significant difference（χ-2=5.715, P〈0.05）. The overall incidence of adverse reactions in study group and control group was 56.3%（18/32） and 71.4%（20/28）, respectively, though there was no significant difference observed（χ-2=0.287, P〉0.05）. After treatment, the level of CEA and CA72-4 decreased significantly in study group compared with control group（P〈0.05）; and there was marked difference regarding the level of CEA and CA72-4 between the two groups（P〈0.05）. Conclusion Endostar combined with paclitaxel and capecitabine may offer good short-term efficacy in the treatment of advanced gastric cancer patients with peritoneal metastasis, with high disease control rate, less adverse reactions, and acceptable safety.